New hope for rare skin disease: bimzelx trial launches
NCT ID NCT07497620
First seen Mar 28, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study tests whether the drug Bimzelx (bimekizumab) can improve skin symptoms in adults with pityriasis rubra pilaris, a rare condition causing red, scaly patches. About 12 participants will receive the drug for 24 weeks, and doctors will measure how much the skin clears. The goal is to see if Bimzelx can control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
Conditions
Explore the condition pages connected to this study.